Lupin Of India Counts On Global Generics Push To Increase Profits
This article was originally published in PharmAsia News
The expansion by India's Lupin into U.S. and Japan markets is generating a company forecast of an increase of as much as 37 percent in profit and sales during the current financial year. Lupin is relying on the push in the world's two largest markets to get patients to use generics to drive its profit increase. The global market for generics is growing at double that of branded drugs because of perceived government needs to trim expenses. Lupin Managing Director Kamal Sharma said his company also plans to acquire more firms and technology to help meet the global demand. (Click here for more
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.